| Literature DB >> 35518733 |
Muhammad Saif Ur Rahman1,2, Muhammad Asif Tahir3, Saima Noreen3, Muhammad Yasir4, Ijaz Ahmad5, Muhammad Bilal Khan3, Khawajah Waqar Ali6, Muhammad Shoaib5, Ali Bahadur7, Shahid Iqbal8.
Abstract
A combination of chemotherapy with hyperthermia can produce remarkable success in treating advanced cancers. For this purpose, magnetite (Fe3O4)-doped mesoporous bioactive glass nanoparticles (Fe3O4-MBG NPs) were synthesized by the sol-gel method. Fe3O4-MBG NPs were found to possess spherical morphology with a size of approximately 50 ± 10 nm and a uniform pore size of 9 nm. The surface area (309 m2 g-1) was sufficient for high drug loading capacity and mitomycin C (Mc), an anticancer drug, was entrapped in the Fe3O4-MBG NPs. A variable rate of drug release was observed at different pH values (6.4, 7.4 & 8.4) of the release media. No significant death of normal human fibroblast (NHFB) cells was observed during in vitro analysis and for Mc-Fe3O4-MBG NPs considerable inhibitory effects on the viability of cancer cells (MG-63) were observed. When Fe3O4-MBG NPs were immersed in simulated body fluid (SBF), hydroxycarbonate apatite (HCA) was formed, as confirmed by XRD and FTIR spectra. A negligible value of coercivity and zero remanence confirms that Fe3O4-MBG NPs are superparamagnetic. Fe3O4-MBG NPs showed a hyperthermia effect in an alternating magnetic field (AMF), and a rise of 11.5 °C in temperature during the first 6 min, making it suitable for hyperthermia applications. Fe3O4-MBG NPs expressed excellent biocompatibility and low cytotoxicity, therefore, they are a safe biomaterial for bone tissue regeneration, drug delivery, and hyperthermia treatment. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35518733 PMCID: PMC9054387 DOI: 10.1039/c9ra09349d
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1BET surface area measurements (inset) pore size distribution of Fe3O4-MBG.
Fig. 2(a) XRD analysis (b) FTIR spectra of Fe3O4-MBG before and after apatite formation.
Fig. 3(a) SEM image and (b) TEM image.
Fig. 4(a) MTT assay of Fe3O4-MBG against NHFB and MG-63 cells, Mc-Fe3O4-MBG against MG-63 cancer cells (b) ALP activity and (c) osteocalcin level reflects the bone-forming property of Fe3O4-MBG.
Fig. 5(a) Cumulative drug release (%) as a function of time for Fe3O4-MBG (b) M–H loop for Fe3O4-MBG at room temperature.
Fig. 6(a) MTT assay (b) temperature kinetics of magnetic hyperthermia study of Fe3O4-MBG at f = 250 kHz.
Properties of Fe3O4-MBG
| Sample | Size (nm) | Pore size (nm) | Surface area (m2 g−1) |
|
| SAR (W g−1) | IC50 of Mc-Fe3O4-MBG (μg mL−1) | Loaded drug | Released drug |
|---|---|---|---|---|---|---|---|---|---|
| Fe3O4-MBG | 50 ± 5 | 9.52 | 309 | 14.16 | 0 | 305.45 | 12.19 | 93% | 42–72% |